Genta to Present at Needham & Company Second Annual Biotechnology Conference
BERKELEY HEIGHTS, N.J., June 4 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq:GNTA) today announced its participation at the Needham & Company Second Annual Biotechnology Conference in New York, NY. William Keane, Genta's Chief Financial Officer, will provide an update on the Company's late-stage development program on Thursday, June 5, 2003 at 3:30 p.m. EST.
A live audio webcast of the presentation can be accessed through Genta's Investor Relations site at: genta.com. A replay will be available for 90 days following the presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA/DNA-based medicines) and small molecules. Genasense(TM) (oblimersen sodium), the Company's lead compound from its oligonucleotide program, is being developed with Aventis and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite(TM) (gallium nitrate injection), which the Company intends to launch later this year for treatment of cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com.
This press release and the webcast to follow contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2002.
SOURCE Genta Incorporated
CO: Genta Incorporated
ST: New Jersey
SU: TDS
Web site: genta.com
prnewswire.com
06/04/2003 15:13 EDT |
